Risk factors and clinical outcomes of cytomegalovirus infection following haploidentical hematopoietic stem cell transplantation in patients with aplastic anemia: a single-center retrospective study.

IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Frontiers in Medicine Pub Date : 2025-01-29 eCollection Date: 2024-01-01 DOI:10.3389/fmed.2024.1523909
Jia Feng, Xinhe Zhang, Zhengwei Tan, Yuechao Zhao, Huijin Hu, Junfa Chen, Liqiang Wu, Qinghong Yu, Dijiong Wu, Baodong Ye, Wenbin Liu
{"title":"Risk factors and clinical outcomes of cytomegalovirus infection following haploidentical hematopoietic stem cell transplantation in patients with aplastic anemia: a single-center retrospective study.","authors":"Jia Feng, Xinhe Zhang, Zhengwei Tan, Yuechao Zhao, Huijin Hu, Junfa Chen, Liqiang Wu, Qinghong Yu, Dijiong Wu, Baodong Ye, Wenbin Liu","doi":"10.3389/fmed.2024.1523909","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cytomegalovirus (CMV) infection remains a critical cause of mortality after allogeneic hematopoietic stem cell transplantation, despite significant advancements in CMV prevention and treatment with the introduction and widespread use of letermovir. However, in China, due to limitations in the availability and cost of medications, some patients still face challenges in accessing letermovir. For this subset of the population, exploring the risk factors for CMV infection remains significant in predicting its occurrence.</p><p><strong>Methods: </strong>Therefore, a retrospective analysis was conducted on 88 haploidentical hematopoietic stem cell transplant recipients over 4 years.</p><p><strong>Results: </strong>Our study results indicate that chronic graft-versus-host disease (cGVHD) is an independent risk factor for CMV infection following haploidentical hematopoietic stem cell transplantation (Haplo-HSCT). Survival analysis reveals lower survival rates in the refractory CMV infection (RCI) group compared to the non-RCI group, with patients having lower viral loads demonstrating higher rates of seroconversion and improved survival under the same treatment regimen.</p><p><strong>Conclusion: </strong>Strengthening the monitoring of CMV-DNA in post-transplant patients, actively promoting hematopoietic recovery, preventing the occurrence of CMV infection, and controlling the development of CMV infection can lead to better survival outcomes for patients with aplastic anemia undergoing Haplo-HSCT.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"11 ","pages":"1523909"},"PeriodicalIF":3.1000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815662/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2024.1523909","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cytomegalovirus (CMV) infection remains a critical cause of mortality after allogeneic hematopoietic stem cell transplantation, despite significant advancements in CMV prevention and treatment with the introduction and widespread use of letermovir. However, in China, due to limitations in the availability and cost of medications, some patients still face challenges in accessing letermovir. For this subset of the population, exploring the risk factors for CMV infection remains significant in predicting its occurrence.

Methods: Therefore, a retrospective analysis was conducted on 88 haploidentical hematopoietic stem cell transplant recipients over 4 years.

Results: Our study results indicate that chronic graft-versus-host disease (cGVHD) is an independent risk factor for CMV infection following haploidentical hematopoietic stem cell transplantation (Haplo-HSCT). Survival analysis reveals lower survival rates in the refractory CMV infection (RCI) group compared to the non-RCI group, with patients having lower viral loads demonstrating higher rates of seroconversion and improved survival under the same treatment regimen.

Conclusion: Strengthening the monitoring of CMV-DNA in post-transplant patients, actively promoting hematopoietic recovery, preventing the occurrence of CMV infection, and controlling the development of CMV infection can lead to better survival outcomes for patients with aplastic anemia undergoing Haplo-HSCT.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
再生障碍性贫血患者单倍体造血干细胞移植后巨细胞病毒感染的危险因素和临床结局:一项单中心回顾性研究
背景:巨细胞病毒(CMV)感染仍然是异基因造血干细胞移植后死亡的一个重要原因,尽管随着莱特莫韦的引入和广泛使用,巨细胞病毒的预防和治疗取得了重大进展。然而,在中国,由于药物可得性和成本的限制,一些患者在获得莱替莫韦方面仍然面临挑战。对于这部分人群,探索巨细胞病毒感染的危险因素对于预测其发生仍然具有重要意义。方法:回顾性分析88例单倍体造血干细胞移植受者4年以上的临床资料。结果:我们的研究结果表明,慢性移植物抗宿主病(cGVHD)是单倍体造血干细胞移植(haploo - hsct)后巨细胞病毒感染的独立危险因素。生存分析显示,与非RCI组相比,难治性巨细胞病毒感染(RCI)组的生存率较低,在相同的治疗方案下,病毒载量较低的患者表现出更高的血清转换率和生存率。结论:加强对移植后患者CMV- dna的监测,积极促进造血功能恢复,预防CMV感染的发生,控制CMV感染的发展,可使接受单倍造血干细胞移植的再生障碍性贫血患者获得更好的生存结局。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers in Medicine
Frontiers in Medicine Medicine-General Medicine
CiteScore
5.10
自引率
5.10%
发文量
3710
审稿时长
12 weeks
期刊介绍: Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate - the use of patient-reported outcomes under real world conditions - the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines - the scientific bases for guidelines and decisions from regulatory authorities - access to medicinal products and medical devices worldwide - addressing the grand health challenges around the world
期刊最新文献
Two-year clinical outcomes of standalone gonioscopy-assisted transluminal trabeculotomy in normal-tension glaucoma. Phenotype-informed management of preoperative asymptomatic isolated muscular calf vein thrombosis in patients undergoing primary total knee arthroplasty under standardized thromboprophylaxis: a retrospective cohort study. Clinical effects of integrated Chinese medicine therapy for postpartum pelvic floor dysfunction: a prospective patient-preference cohort study. Case Report: IgG4-related autoimmune pancreatitis presenting as an infiltrative cystic-solid pancreatic mass: lessons from a diagnostic pitfall. Clinical features and prognostic factors of Chlamydia psittaci pneumonia: a retrospective study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1